IMYSF yields 3.52% · JNJ yields 2.13%● Live data
📍 IMYSF pulled ahead of the other in Year 1
Combined, IMYSF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of IMYSF + JNJ for your $10,000?
Imerys S.A. provides mineral-based specialty solutions for various industries worldwide. The company operates in Performance Minerals and High Temperature Solutions segments. It provides additives for interior decorative paints, as well as marine protection, facade coating, can coating, etc.; rubber, tires, medical rubber, and cables; and adhesives and sealants. The company also offers minerals for technical ceramics and traditional ceramics comprising floor and wall tiles, large slabs, sanitaryware, and tableware; and components for the production of high purity silicon metal for used to manufacture aluminum alloys, electronics, and solar panels, as well as for construction industry, such as insulation ceiling tiles. In addition, it provides functional additives for plastics and thermoset for use in automotive, construction, packaging, and hygiene industries; fillers and coatings for graphic paper, as well as board and packaging applications; filtration agents for liquids and blood plasma; and graphite and carbon-based solutions for lithium-ion and alkaline batteries, polymers, fuel cells, carbon brushes, and others. Further, the company offers refractory minerals and solutions for high-temperature industrial processes; bentonite for foundry molds; alumina and zirconia for abrasives; and high-performance binders for dry mix mortars and floor screeds in the construction industry. It serves construction, paper and board, mobile energy, steelmaking, agriculture, food, automotive, and cosmetics industries. The company was incorporated in 1880 and is headquartered in Paris, France. Imerys S.A. is a subsidiary of Belgian Securities BV.
Full IMYSF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.